Background. The combined measles, mumps, and rubella (MMR) vaccine has been
successfully administered for> 20 years. Because of this, protection by maternal antibodies …

The decay of maternally derived antibodies to measles, mumps, and rubella viruses in Swiss
infants was studied in order to determine the optimal time for vaccination. A total of 500 …

Aims In recent years, Europe has recorded an increase in the number of measles outbreaks
despite the implementation of vaccination into the National Immunization Programs. The …

Measles and mumps, but not rubella, outbreaks have been reported amongst populations
highly vaccinated with a single dose of measles–mumps–rubella (MMR) vaccine. Repeated …

Serum antibodies against measles were measured in the Dutch general population and in
municipalities with low vaccine coverage, where religious groups that refuse vaccination are …

The evolution of measles-and rubella-specific serum IgG was followed in a longitudinal
study in 224 young adolescent vaccinees, with or without boost vaccination before or during …

A serological prevalence survey was carried out in Luxembourg during 2000–2001 to
determine the antibody status of the Luxembourg population against vaccine-preventable …

Objective To investigate the duration of the presence of maternal antibodies to measles in
infants. Design Prospective study (May 2006 to November 2008). Setting Five hospitals in …

Background The persistence of antibodies against measles, mumps, and rubella induced by
the measles-mumps-rubella (MMR) vaccine and the kinetics of antibody decline after the …

WHO–Europe's goal is to eliminate measles and rubella by 2010 which will require a
coverage rate of 95% for both MMR-vaccine doses. Belgian recommendations include a first …